{"url_path":"/sec/nvct/8-k/2026-06-30/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ** **Financial","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1875558/0001104659-26-079360-index.html","accession_number":"0001104659-26-079360","cik":"0001875558","ticker":"NVCT","issuer_name":"Nuvectis Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1875558/0001104659-26-079360-index.html","primary_entity_key":"0001875558","primary_entity_name":"Nuvectis Pharma, Inc."},"word_count":141,"has_tables":true,"body_markdown":"**Item 9.01.** **Financial\nStatements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\nThe following exhibits are filed as a part of this\nreport:\n\n \n\n**Exhibit\nNumber**\n \n**Description**\n\n[1.1](tm2619346d1_ex1-1.htm)\n \n[Underwriting Agreement, dated June 29, 2026, between\nNuvectis Pharma, Inc. and Cantor Fitzgerald & Co.](tm2619346d1_ex1-1.htm)\n\n[5.1](tm2619346d1_ex5-1.htm)\n \n[Opinion of Alston & Bird LLP.](tm2619346d1_ex5-1.htm)\n\n[23.1](tm2619346d1_ex5-1.htm)\n \n[Consent of Alston & Bird LLP (included in\nthe opinion filed as Exhibit 5.1).](tm2619346d1_ex5-1.htm)\n\n[99.1](tm2619346d1_ex99-1.htm)\n \n[Launch Press Release, dated June 29, 2026.](tm2619346d1_ex99-1.htm)\n\n[99.2](tm2619346d1_ex99-2.htm)\n \n[Pricing Press Release, dated June 29, 2026.](tm2619346d1_ex99-2.htm)\n\n104\n \nCover Page Interactive Data File, formatted in\nInline Extensible Business Reporting Language (iXBRL).\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf\nby the undersigned hereunto duly authorized.\n\n \n\n \n**Nuvectis Pharma, Inc.**\n\n \n(Registrant)\n\n \n \n \n\nDate: June 30, 2026\n \n \n\n \nBy:\n/s/ Ron Bentsur\n\n \n \nRon Bentsur\n\n \n \nChairman, Chief Executive Officer and President"}